Capital One Financial Equities Analysts Lower Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYAFree Report) – Analysts at Capital One Financial decreased their FY2026 EPS estimates for IDEAYA Biosciences in a research note issued to investors on Monday, July 8th. Capital One Financial analyst T. Chiang now anticipates that the company will earn ($2.58) per share for the year, down from their previous forecast of ($2.17). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.37) per share. Capital One Financial also issued estimates for IDEAYA Biosciences’ FY2027 earnings at ($1.16) EPS and FY2028 earnings at $3.02 EPS.

Several other research analysts have also weighed in on IDYA. Stifel Nicolaus reissued a “buy” rating and set a $63.00 price objective on shares of IDEAYA Biosciences in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $56.00 price objective (up from $52.00) on shares of IDEAYA Biosciences in a research report on Monday. Mizuho initiated coverage on shares of IDEAYA Biosciences in a research report on Monday. They issued an “outperform” rating and a $50.00 price objective on the stock. Citigroup raised their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Finally, BTIG Research raised their target price on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday. Fourteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $51.42.

Check Out Our Latest Report on IDYA

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $37.32 on Thursday. The firm has a market cap of $2.82 billion, a P/E ratio of -18.57 and a beta of 0.86. IDEAYA Biosciences has a 1-year low of $20.90 and a 1-year high of $47.74. The firm has a fifty day moving average of $38.37 and a two-hundred day moving average of $40.71.

IDEAYA Biosciences (NASDAQ:IDYAGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. The business’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.49) EPS.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently modified their holdings of IDYA. Federated Hermes Inc. boosted its holdings in IDEAYA Biosciences by 14.8% in the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after purchasing an additional 500,046 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter worth approximately $12,328,000. Charles Schwab Investment Management Inc. grew its position in shares of IDEAYA Biosciences by 13.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 496,456 shares of the company’s stock worth $17,664,000 after buying an additional 59,100 shares during the period. Campbell & CO Investment Adviser LLC grew its position in shares of IDEAYA Biosciences by 93.2% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 61,226 shares of the company’s stock worth $2,178,000 after buying an additional 29,536 shares during the period. Finally, First Light Asset Management LLC bought a new position in IDEAYA Biosciences during the 4th quarter worth approximately $12,299,000. 98.29% of the stock is owned by institutional investors.

Insider Transactions at IDEAYA Biosciences

In related news, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total value of $1,032,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Yujiro S. Hata sold 56,711 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at approximately $28,206,878.07. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Anthony White sold 28,500 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 119,644 shares of company stock valued at $4,832,228. 3.50% of the stock is owned by insiders.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Further Reading

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.